Literature DB >> 2495079

Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin.

P J Prichard1, G K Kitchingman, R P Walt, T K Daneshmend, C J Hawkey.   

Abstract

OBJECTIVE: To investigate the suitability of treatment with low dose aspirin or warfarin, or both, as possible prophylaxis against cardiovascular disease by determining the effect on gastric mucosal bleeding.
DESIGN: Randomised crossover trial.
SETTING: Academic department of therapeutics.
SUBJECTS: Twenty healthy male volunteers aged 19-22.
INTERVENTIONS: On separate occasions and in randomised order all subjects received aspirin 75 mg, warfarin, or aspirin 75 mg combined with warfarin. Each treatment was given for 12 days or (when warfarin was used) for longer if necessary until the international normalised ratio of the prothrombin time was stable at 1.4-1.6. END POINT: Loss of blood over 10 minutes into gastric washings.
MEASUREMENTS AND MAIN RESULTS: Bleeding over 10 minutes into gastric washings under baseline conditions and after five days, and at end of each regimen of treatment. Aspirin 75 mg increased bleeding from 0.60 (95% confidence interval 0.36 to 0.99) microliters/10 minutes to 1.26 (0.71 to 2.25) microliters/10 minutes at five days, with no evidence of either progressive change or adaptation thereafter. Warfarin had no effect on bleeding either alone or when combined with aspirin.
CONCLUSIONS: Aspirin 75 mg causes gastric mucosal bleeding. Low dose warfarin neither induces gastric mucosal bleeding nor enhances that caused by aspirin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495079      PMCID: PMC1835778          DOI: 10.1136/bmj.298.6672.493

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  27 in total

1.  Aspirin and gastrointestinal bleeding. Chromate blood loss studies.

Authors:  R N PIERSON; P R HOLT; R M WATSON; R P KEATING
Journal:  Am J Med       Date:  1961-08       Impact factor: 4.965

2.  Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.

Authors:  K Breddin; D Loew; K Lechner; K Uberla; E Walter
Journal:  Thromb Haemost       Date:  1979-02-28       Impact factor: 5.249

3.  Aspirin and secondary mortality after myocardial infarction.

Authors:  P C Elwood; P M Sweetnam
Journal:  Lancet       Date:  1979 Dec 22-29       Impact factor: 79.321

4.  Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis.

Authors:  S P Hanley; J Bevan; S R Cockbill; S Heptinstall
Journal:  Lancet       Date:  1981-05-02       Impact factor: 79.321

5.  Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death.

Authors:  M J Davies; A Thomas
Journal:  N Engl J Med       Date:  1984-05-03       Impact factor: 91.245

6.  Aspirin, paracetamol, and haematemesis and melaena.

Authors:  D Coggon; M J Langman; D Spiegelhalter
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

7.  Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis.

Authors:  M J Stuart; S J Gross; H Elrad; J E Graeber
Journal:  N Engl J Med       Date:  1982-10-07       Impact factor: 91.245

8.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

Authors:  H D Lewis; J W Davis; D G Archibald; W E Steinke; T C Smitherman; J E Doherty; H W Schnaper; M M LeWinter; E Linares; J M Pouget; S C Sabharwal; E Chesler; H DeMots
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

9.  Haemostatic function and cardiovascular death: early results of a prospective study.

Authors:  T W Meade; W R North; R Chakrabarti; Y Stirling; A P Haines; S G Thompson; M Brozovié
Journal:  Lancet       Date:  1980-05-17       Impact factor: 79.321

10.  A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.

Authors:  P C Elwood; A L Cochrane; M L Burr; P M Sweetnam; G Williams; E Welsby; S J Hughes; R Renton
Journal:  Br Med J       Date:  1974-03-09
View more
  15 in total

Review 1.  Recognition and treatment of unstable angina.

Authors:  C Brunelli; P Spallarossa; P Rossettin; S Caponnetto
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

2.  Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin.

Authors:  Lulu Iles-Shih; Judy F Collins; Jennifer L Holub; David A Lieberman
Journal:  Am J Gastroenterol       Date:  2010-08-03       Impact factor: 10.864

Review 3.  Adverse reactions and interactions with aspirin. Considerations in the treatment of the elderly patient.

Authors:  J Karsh
Journal:  Drug Saf       Date:  1990 Sep-Oct       Impact factor: 5.606

Review 4.  Selective inhibitors of cyclooxygenase-2. Potential in elderly patients.

Authors:  N M Davies; J L Wallace
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

5.  Gastrointestinal blood loss after non-steroidal anti-inflammatory drugs. Measurement by selective determination of faecal porphyrins.

Authors:  A Cohen; J K Boeijinga; P M van Haard; R C Schoemaker; A van Vliet-Verbeek
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

6.  Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis.

Authors:  A B Hawthorne; Y R Mahida; A T Cole; C J Hawkey
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

7.  Prophylactic aspirin and risk of peptic ulcer bleeding.

Authors:  J Weil; D Colin-Jones; M Langman; D Lawson; R Logan; M Murphy; M Rawlins; M Vessey; P Wainwright
Journal:  BMJ       Date:  1995-04-01

8.  Low-dose acetylsalicylic acid use and hemoglobin levels. Effects in a primary care population.

Authors:  A Leibovici; N Lavi; S Wainstok; J Herman; V W Greene
Journal:  Can Fam Physician       Date:  1995-01       Impact factor: 3.275

9.  Gastro-duodenal injury associated with intake of 100-325 mg aspirin daily.

Authors:  R Oren; M Ligumsky; J Lysy; J Gonzales; J Zimmerman
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

Review 10.  Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer. At what cost?

Authors:  M A Trujillo; H S Garewal; R E Sampliner
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.